Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Andrew Haydon"'
Autor:
C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous
Publikováno v:
European Journal of Cancer, 151, 72-83. Elsevier Ltd.
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
Introduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy f
Autor:
Michael Millward, V. Atkinson, Sandip Pravin Patel, Christoph Hoeller, Christian U. Blank, Andrew Haydon, Alexander N. Shoushtari, Reinhard Dummer, Alexander M. Menzies, James Larkin, Carina N. Owen, Arissa Young, Maartje W. Rohaan, Dharmisha Chauhan, Shahneen Sandhu, Douglas B. Johnson, J. Mangana, Georgina V. Long, D. Palmieri, Matteo S. Carlino, Serigne Lo, Muhammad A. Khattak, Farzana Y Zaman, Peter Hersey, Belinda Lee
Publikováno v:
Ann Oncol
Background: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%-30% of patients recur within 1 year. This study describes the pattern of recurrence,
Autor:
Prachi Bhave, Andrew Haydon
Publikováno v:
Australasian Journal of Dermatology. 61:203-209
Stage III melanoma involves regional lymph nodes and/or in-transit or satellite disease, without spread to distant metastatic sites. Stage IIIA melanoma includes a T1a-T2a primary lesion with N1a or N2a nodal involvement, whilst stage IIID melanoma i
Autor:
B. Mark Smithers, Andrew Haydon, Rachel Roberts-Thomson, Richard C. W. Martin, Robyn P. M. Saw, John F. Thompson, Victoria Atkinson, David E. Gyorki
Publikováno v:
ANZ journal of surgeryREFERENCES. 91
Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care p
Autor:
Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
Publikováno v:
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
Autor:
James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
Publikováno v:
Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020
European Journal of Cancer, 116, 148-157
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020
European Journal of Cancer, 116, 148-157
Background: The American Joint Committee on Cancer-8 (AJCC) classification of melanoma was implemented in January 2018. It was based on data gathered when checkpoint inhibitors were not used as adjuvant therapy in stage III melanoma. The European Org
Autor:
John W Kelly, Andrew Haydon, Rory Wolfe, Nikki R Adler, Catriona McLean, Grant A. McArthur, Victoria Mar
Publikováno v:
British Journal of Cancer
Background A proportion of patients develop recurrence following a tumour-negative sentinel lymph node biopsy (SLNB). This study aimed to explore whether melanoma patients with BRAF or NRAS mutant tumours have an increased risk of developing disease
Autor:
Nicholas J. Cummings, Andrew Haydon, John W Kelly, Nikki R Adler, Grant A. McArthur, Victoria Mar, Catriona McLean, Thien Tra, Rory Wolfe
Publikováno v:
Pigment Cell & Melanoma Research. 31:592-603
This study aimed to determine the frequency and concordance of BRAF and NRAS mutation in tumours arising in patients with multiple primary melanoma (MPM). Patients with MPM managed at one of three tertiary referral centres in Melbourne, Australia, fr
Autor:
Vanna Chiarion-Sileni, M. Mandal, A. Hauschild, Bijoyesh Mookerjee, R. Ji, Jeffrey J. Legos, John M. Kirkwood, Victoria Atkinson, Jacob Schachter, James Larkin, Richard F. Kefford, Ping Zhang, Caroline Robert, Caroline Dutriaux, M. Santinami, Andrew Haydon, Dirk Schadendorf, Georgina V. Long, Thierry Lesimple, Reinhard Dummer, Laurent Mortier, Marta Nyakas, Ruth Plummer
Publikováno v:
New England Journal of Medicine. 377:1813-1823
Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve o
Autor:
Alexander Menzies, Prachi Bhave, Alison Weppler, Lauren Julia Brown, Georgina V. Long, Douglas B. Johnson, Clara Allayous, Shahneen Sandhu, Andrew Haydon, Patrick A. Ott, J. Randall Patrinely, Matteo S. Carlino, Céleste Lebbé
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundClinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospe